135 related articles for article (PubMed ID: 9676822)
1. Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results.
Broocks A; Pigott TA; Hill JL; Canter S; Grady TA; L'Heureux F; Murphy DL
Psychiatry Res; 1998 Jun; 79(1):11-20. PubMed ID: 9676822
[TBL] [Abstract][Full Text] [Related]
2. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder.
Pigott TA; Zohar J; Hill JL; Bernstein SE; Grover GN; Zohar-Kadouch RC; Murphy DL
Biol Psychiatry; 1991 Mar; 29(5):418-26. PubMed ID: 2018816
[TBL] [Abstract][Full Text] [Related]
3. Behavioral, physiological and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment.
Broocks A; Briggs NC; Pigott TA; Hill JL; Canter SK; Tolliver TJ; Baldemore D; Murphy DL
Psychopharmacology (Berl); 1997 Mar; 130(2):91-103. PubMed ID: 9106905
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP.
Pigott TA; Hill JL; Grady TA; L'Heureux F; Bernstein S; Rubenstein CS; Murphy DL
Biol Psychiatry; 1993 Jan; 33(1):3-14. PubMed ID: 8420593
[TBL] [Abstract][Full Text] [Related]
5. Acute and chronic role of 5-HT3 neuronal system on behavioral and neuroendocrine changes induced by intravenous cholecystokinin tetrapeptide administration in humans.
Dépôt M; Caillé G; Mukherjee J; Katzman MA; Cadieux A; Bradwejn J
Neuropsychopharmacology; 1999 Feb; 20(2):177-87. PubMed ID: 9885797
[TBL] [Abstract][Full Text] [Related]
6. Serotonergic function in social phobia: comparison to normal control and obsessive-compulsive disorder subjects.
Hollander E; Kwon J; Weiller F; Cohen L; Stein DJ; DeCaria C; Liebowitz M; Simeon D
Psychiatry Res; 1998 Jul; 79(3):213-7. PubMed ID: 9704868
[TBL] [Abstract][Full Text] [Related]
7. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers.
Hollander E; DeCaria CM; Nitescu A; Gully R; Suckow RF; Cooper TB; Gorman JM; Klein DF; Liebowitz MR
Arch Gen Psychiatry; 1992 Jan; 49(1):21-8. PubMed ID: 1728249
[TBL] [Abstract][Full Text] [Related]
8. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects.
Charney DS; Goodman WK; Price LH; Woods SW; Rasmussen SA; Heninger GR
Arch Gen Psychiatry; 1988 Feb; 45(2):177-85. PubMed ID: 3337615
[TBL] [Abstract][Full Text] [Related]
9. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology.
Zohar J; Insel TR
Biol Psychiatry; 1987 Jun; 22(6):667-87. PubMed ID: 3036259
[TBL] [Abstract][Full Text] [Related]
10. Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor.
Stein DJ; Van Heerden B; Wessels CJ; Van Kradenburg J; Warwick J; Wasserman HJ
Prog Neuropsychopharmacol Biol Psychiatry; 1999 Aug; 23(6):1079-99. PubMed ID: 10621951
[TBL] [Abstract][Full Text] [Related]
11. Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action.
Benkelfat C; Murphy DL; Zohar J; Hill JL; Grover G; Insel TR
Arch Gen Psychiatry; 1989 Jan; 46(1):23-8. PubMed ID: 2910220
[TBL] [Abstract][Full Text] [Related]
12. Serotonergic modulation of anticholinergic effects on cognition and behavior in elderly humans.
Little JT; Broocks A; Martin A; Hill JL; Tune LE; Mack C; Cantillon M; Molchan S; Murphy DL; Sunderland T
Psychopharmacology (Berl); 1995 Aug; 120(3):280-8. PubMed ID: 8524975
[TBL] [Abstract][Full Text] [Related]
13. Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder.
Hewlett WA; Schmid SP; Salomon RM
J Clin Psychiatry; 2003 Sep; 64(9):1025-30. PubMed ID: 14628977
[TBL] [Abstract][Full Text] [Related]
14. Biological and behavioral responses to D-amphetamine, alone and in combination with the serotonin3 receptor antagonist ondansetron, in healthy volunteers.
Grady TA; Broocks A; Canter SK; Pigott TA; Dubbert B; Hill JL; Murphy DL
Psychiatry Res; 1996 Aug; 64(1):1-10. PubMed ID: 8888359
[TBL] [Abstract][Full Text] [Related]
15. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment.
Zohar J; Insel TR; Zohar-Kadouch RC; Hill JL; Murphy DL
Arch Gen Psychiatry; 1988 Feb; 45(2):167-72. PubMed ID: 3276283
[TBL] [Abstract][Full Text] [Related]
16. The influence of ondansetron and m-chlorophenylpiperazine on scopolamine-induced cognitive, behavioral, and physiological responses in young healthy controls.
Broocks A; Little JT; Martin A; Minichiello MD; Dubbert B; Mack C; Tune L; Murphy DL; Sunderland T
Biol Psychiatry; 1998 Mar; 43(6):408-16. PubMed ID: 9532345
[TBL] [Abstract][Full Text] [Related]
17. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation.
Goodman WK; McDougle CJ; Price LH; Barr LC; Hills OF; Caplik JF; Charney DS; Heninger GR
Biol Psychiatry; 1995 Aug; 38(3):138-49. PubMed ID: 7578657
[TBL] [Abstract][Full Text] [Related]
18. Effects of various serotonin receptor subtype-selective antagonists alone and on m-chlorophenylpiperazine-induced neuroendocrine changes in rats.
Aulakh CS; Hill JL; Murphy DL
J Pharmacol Exp Ther; 1992 Nov; 263(2):588-95. PubMed ID: 1432690
[TBL] [Abstract][Full Text] [Related]
19. Increased cerebral blood flow during m-CPP exacerbation of obsessive-compulsive disorder.
Hollander E; Prohovnik I; Stein DJ
J Neuropsychiatry Clin Neurosci; 1995; 7(4):485-90. PubMed ID: 8555752
[TBL] [Abstract][Full Text] [Related]
20. Obsessive-compulsive disorder as a 5-HT subsystem-related behavioural disorder.
Murphy DL; Zohar J; Benkelfat C; Pato MT; Pigott TA; Insel TR
Br J Psychiatry Suppl; 1989 Dec; (8):15-24. PubMed ID: 2692636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
